Results 1 to 10 of about 14,298 (222)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma [PDF]

Biomolecules, 2022
Neuroblastoma is one of the few childhood cancers that carries a tumor-specific antigen in the form of a glycolipid antigen known as GD2. It has restricted expression in normal tissue, such as peripheral afferent nerves.
Godfrey Chi-Fung Chan, Carol Matias Chan
exaly   +4 more sources

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype

Biomedicines, 2020
The tumor-associated ganglioside GD2 represents an attractive target for cancer immunotherapy. GD2-positive tumors are more responsive to such targeted therapy, and new methods are needed for the screening of GD2 molecular tumor phenotypes. In this work,
Roman Kholodenko, Maksim Sorokin, Daniel Kalinovsky   +2 more
exaly   +4 more sources

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Frontiers in Oncology, 2020
Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is
Bassel Nazha, Taofeek Owonikoko
exaly   +3 more sources

Anti-GD2 immunotherapy for neuroblastoma [PDF]

Expert Review of Anticancer Therapy, 2017
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents.
Shakeel Modak
exaly   +3 more sources

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human [PDF]

OncoImmunology
Despite advances in anti-disialoganglioside (GD2) immunotherapy, high-risk neuroblastoma (NB) remains a clinical challenge. Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity is a potent mechanism of action of anti-GD2 antibody ...
Mengjia Song, Yingxia Lan, Xiya Tan, Linnan Wu, Jia Zhu, Suying Lu, Feifei Sun, Min Gao, Junting Huang, Yi Que, Yu Zhang, Xiaona Fang, Mengzhen Li, Yumiao Mai, Juan Wang, Tong Xiang, Yizhuo Zhang   +16 more
doaj   +2 more sources

Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors [PDF]

Scientific Reports
Lung cancer remains one of the most prevalent and lethal malignancies worldwide, with persistently poor 5-year survival rates across all stages. The development of novel therapies is therefore crucial for overcoming treatment resistance, improving ...
Nunghathai Sawasdee, Aussara Panya, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Chutamas Thepmalee   +4 more
doaj   +2 more sources

Ganglioside GD2 is a potential candidate marker for lung cancer stem cells [PDF]

Jichu yixue yu linchuang, 2023
Objective To explore the feasibility of ganglioside GD2 as a marker for lung cancer stem cells (LCSCs). Methods Cancer stem cells (CSCs) of lung cancer cell lines were enriched by spheroid culturing in vitro; The expression of stemness-related genes ...
LI Zhen, DUAN Zhaojun, LUO Yunping
doaj   +1 more source

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas

Frontiers in Immunology, 2023
BackgroundDiffuse intrinsic pontine gliomas (DIPGs) are rare and fatal pediatric brainstem gliomas with no cure. Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have been proven effective in treating glioblastoma (GBM) in preclinical
Pengcheng Zuo, Yaopeng Li, Chi He, Tantan Wang, Xu Zheng, Hao Liu, Zhen Wu, Junting Zhang, Xuebin Liao, Xuebin Liao, Liwei Zhang, Liwei Zhang   +11 more
doaj   +1 more source

Anti-GD2 Antibody Therapy for GD2-Expressing Tumors [PDF]

Current Cancer Drug Targets, 2010
In the development of novel immune therapies for high-risk cancers, one goal is to find tumor targets that are not widely shared by normal cells. One such target is the surface disialoganglioside GD2. This antigen is expressed on the surface of a variety of tumors for which no curative therapies exist for patients with advanced disease.
Fariba, Navid, Victor M, Santana, Raymond C, Barfield   +2 more
openaire   +2 more sources

Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA [PDF]

Journal of Immunological Methods, 2011
Two assay methods for quantification of the disialoganglioside (GD2)-specific binding activities of anti-GD2 monoclonal antibodies and antibody immunofusion proteins, such as ch14.18 and hu14.18-IL2, were developed. The methods differed in the use of either microtiter plates coated with purified GD2 or plates seeded with GD2-expressing cell lines to ...
Gopalan, Soman, Xiaoyi, Yang, Hengguang, Jiang, Steve, Giardina, Gautam, Mitra   +4 more
openaire   +2 more sources